Back to User profile » Dr John M Kane

Papers published by Dr John M Kane:


Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic

Haider B, O'Sullivan AK, Bessonova L, Keane E, Achtyes E, Harvey PD, Kane JM, Saklad SR, Trotter JP, Claxton A, Polak T, McGrory J, Noori W, Sikora Kessler A, Yarlas A, Velligan D

Neuropsychiatric Disease and Treatment 2023, 19:623-634

Published Date: 17 March 2023

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia

Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel PM, Wang S, Richarz U, Gopal S, Kane JM

Neuropsychiatric Disease and Treatment 2023, 19:531-545

Published Date: 7 March 2023

Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile

de Filippis R, Gaetano R, Schoretsanitis G, Verde G, Oliveti CA, Kane JM, Segura-Garcia C, De Fazio P

Neuropsychiatric Disease and Treatment 2021, 17:2141-2150

Published Date: 1 July 2021

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

Jackson R, Brams MN, Citrome L, Hoberg AR, Isaacson SH, Kane JM, Kumar R

Neuropsychiatric Disease and Treatment 2021, 17:1589-1597

Published Date: 24 May 2021

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, Fitzgerald H, Byerly M

Neuropsychiatric Disease and Treatment 2018, 14:1463-1474

Published Date: 8 June 2018

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2

Sajatovic M, Ross R, Legacy SN, Byerly M, Kane JM, DiBiasi F, Fitzgerald H, Correll CU

Neuropsychiatric Disease and Treatment 2018, 14:1475-1492

Published Date: 8 June 2018